表紙:ポイントオブケア分子診断の世界市場2023-2030
市場調査レポート
商品コード
1296870

ポイントオブケア分子診断の世界市場2023-2030

Global Point of Care Molecular Diagnostics Market 2023-2030

出版日: | 発行: Orion Market Research | ページ情報: 英文 100 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
ポイントオブケア分子診断の世界市場2023-2030
出版日: 2023年05月25日
発行: Orion Market Research
ページ情報: 英文 100 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のポイントオブケア分子診断市場は、予測期間中に年平均成長率8.2%で成長すると推定されています。臨床診断の検査時間を短縮する技術に対する研究開発資金の増加が、ポイントオブケア分子診断薬市場の成長を牽引しています。特に、COVID-19の大流行により、規制当局による診断薬の迅速承認への意欲が高まっています。さらに、長期的な外来治療を必要とする慢性疾患の有病率の増加、政府および研究資金の急速なシフト、ライフサイエンス技術におけるエキサイティングな進歩が、市場の成長をさらに押し上げる主な要因となっています。

セグメントの見通し

単核球症分野は好意的な成長率が予測される

用途別では、予測期間中、単核球症分野が市場で大きなシェアを占めています。単核症の成長の主な要因としては、健康意識の高まり、単核症患者の増加、思春期人口の増加などが挙げられます。

地域展望

北米地域が世界のポイントオブケア分子診断市場の成長を牽引

米国がん協会によると、2021年に米国で新たにがんと診断された患者数は189万8,160人、がんによる死亡者数は60万8,570人です。加えて、感染症の有病率の高さ、提携・協業・資金調達戦略への参入により分子診断検査を提供する大手市場プレイヤーの存在が、市場成長を後押しすると予測されます。例えば、2021年12月、Spesana社、EMRs社、Biodesix Inc.は、包括的な肺がん管理のためのSpesana社のデジタルプラットフォームソリューションを活用し、米国全域の臨床ワークフローにおける分子診断の使用をさらに合理化・自動化するために提携したと発表しました。スペサナのクラウドベースのデジタルヘルスケアプラットフォームは、すべてのEMR、ラボ情報システム、分子診断を統合し、医療提供者にとって単純な作業であるべきものが複雑な問題になることがあまりにも多く、しばしば破綻していると考えられている電子医療システムを改善します。

目次

第1章 レポート概要

  • 業界の現状分析と成長の可能性
  • 調査アプリケーションとツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Abbott Laboratories
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Becton, Dickinson and Co.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Bosch Healthcare Solutions GmbH
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Siemens Healthineers
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Thermo Fisher Scientific Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • ポイントオブケア分子診断の世界市場:用途別
    • インフルエンザ
    • 単核球症
    • 呼吸器感染症
    • 消化器感染症
    • 性感染症
    • その他(出生前検査、内分泌学)
  • ポイントオブケア分子診断の世界市場:エンドユーザー別
    • 病院
    • 在宅医療
    • その他(分散型ラボ)
  • ポイントオブケア分子診断の世界市場:技術別
    • PCR法
    • 遺伝子配列決定
    • ハイブリダイゼーション
    • マイクロアレイ

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Accelerate Diagnostics
  • Access Bio
  • Ador Diagnostics
  • ADT Biotech
  • Akonni Biosystems
  • Alveo Technologies
  • Antelope Dx
  • Applied BioCode
  • Aureum Diagnostics
  • Aus Diagnostics
  • Baebies
  • Beckman Coulter Diagnostics
  • Binx Health
  • Biocartis
  • BioFire Diagnostics(bioMerieux)
  • BioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid(Danaher)
  • Credo Diagnostics Biomedical
  • Cue Health
図表

LIST OF TABLES

  • 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR MONONUCLEOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR RESPIRATORY INFECTIOUS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR GASTROINTESTINAL INFECTIOUS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR SEXUALLY TRANSMITTED DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR OTHERS (PRENATAL TESTING, AND ENDOCRINOLOGY) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN HOMCARE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN OTHERS (DECENTRALIZED LABS) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 13. GLOBAL PCR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL GENETIC SEQUENCING POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL HYBRIDIZATION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL MICROARRAY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION , 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY , 2022-2030 ($ MILLION)
  • 22. EUROPEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. EUROPEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION , 2022-2030 ($ MILLION)
  • 24. EUROPEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25. EUROPEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 28. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 29. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY , 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER , 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY , 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR INFLUENZA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR MONONUCLEOSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR RESPIRATORY INFECTIOUS DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR GASTROINTESTINAL INFECTIOUS DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR SEXUALLY TRANSMITTED DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR OTHERS (PRENATAL TESTING, AND ENDOCRINOLOGY) MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY END USER, 2022 VS 2030 (%)
  • 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN HOMECARE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN OTHERS (DECENTRALIZED LABS) MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 13. GLOBAL PCR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL GENETIC SEQUENCING POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL HYBRIDIZATION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL MICROARRAY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027362

Title:Global Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report by Application (Influenza, Mononucleosis, Respiratory Infectious Disease, Gastrointestinal Infectious Disease, Sexually Transmitted Disease, and Others (prenatal testing, and endocrinology)), by End User (Hospitals, Homecare, and Others (decentralized labs)), and by Technology (PCR, Genetic Sequencing, Hybridization, and Microarray) Forecast Period (2022-2030).

Global point of care molecular diagnostics market is estimated to grow at a CAGR of 8.2% during the forecast period. Increased R&D funding for technologies that will reduce clinical diagnostic testing time is driving growth in the point-of-care molecular diagnostics market. Notably, the COVID-19 pandemic has driven greater willingness by regulatory authorities to fast-track approval of diagnostic products. For instance, in April 2020, the US National Institutes of Health (NIH) Point-of-Care Technologies Research Network (POCTRN) launched the Rapid Acceleration of Diagnostics (RADxSM) initiative. The initiative accelerates the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2. In addition, the increased prevalence of chronic diseases that require long-term outpatient care, rapid shifts in government and research funding, and exciting advancements in life science technologies are the major factors that further boost the market growth. According to the Center for Disease Control and Prevention (CDC), almost half of all American adults have high blood pressure, and cardiovascular disease is responsible for one in three deaths, nearly 859,000 people in the US suffered from various chronic diseases in 2022.

Segmental Outlook

The global point of care molecular diagnostics market is segmented based on its application, end user, and technology. Based on application, the market is divided into Influenza, Mononucleosis, Respiratory Infectious Disease, Gastrointestinal Infectious Disease, Sexually Transmitted Diseases, and Others (prenatal testing, and endocrinology). Based on end user, the market is segmented into hospitals, homecare, and others (decentralized labs). Based on technology, the market is categorized into PCR, genetic sequencing, hybridization, and microarray. Based on technology, the PCR segment is projected to grow at a favorable rate. The growth is attributed to the growing use of PCR in proteomics, genomics, and COVID-19 testing, as it is easy-to-use devices are the major factors driving the growth of this market segment.

The Mononucleosis segment is Projected to Grow at a Favorable Rate

Based on application, the Mononucleosis segment holds a significant market share in the market during the forecast period. The major factors responsible for the growth of mononucleosis include rising health awareness, increasing mononucleosis cases, and the rise in the adolescent population. Moreover, infectious mononucleosis mostly affects adolescents and young adults 15 to 24 years of age (6 to 8 cases per 1,000 person-years), particularly those living in communal environments, such as dormitories or military barracks, nearly 11 to 48 cases per 1,000 people were infected by mononucleosis according to the American Heart Association.  

Regional Outlooks

The global point of care molecular diagnostics market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Based on geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Asia Pacific is expected to witness the fastest growth over the forecast period owing to a larger population base, and availability of potential cost-effective implementation of point of care molecular diagnostics tests.

Global Point of Care Molecular Diagnostics Market Growth, by Region 2023-2030

Source: OMR Analysis

The North American Region Leads the Growth of the Global Point of Care Molecular Diagnostics Market

Increasing cases of cancer and well-established healthcare systems are the prominent factors that drive market growth According to the American Cancer Society, in 2021, there were 1,898,160 new cancer cases diagnosed and 608,570 cancer mortality in the US. In addition, the high prevalence of infectious diseases, and the presence of major market players that are offering molecular diagnostics tests by entering into partnership, collaboration, and funding strategy, is projected to boost market growth. For instance, in December 2021, Spesana, EMRs, and Biodesix Inc., announced that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the US utilizing Spesana's digital platform solutions for comprehensive lung cancer management. Spesana cloud-based Digital Healthcare Platform unifying all EMRs, Lab Information Systems and Molecular Diagnostics to improve what is often considered a broken electronic healthcare system that all too frequently turns what should be simple tasks into complex problems for healthcare providers.

\Market Players Outlook

Major companies contributing to the global point of care molecular diagnostics market include Abbott Laboratories, Becton, Dickinson and Co., Bosch Healthcare Solutions GmbH, Siemens Healthineers, Thermo Fisher Scientific Inc., Enzo Biochem, Eurofins Scientific, Fluxergy, and others. The market players are considerably contributing to the market growth by adopting various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. For instance, in March 2023, Global Fund, USAID and Stop TB partnership entered into a collaboration with Molbio Diagnostics, point-of-care molecular diagnostics company and inventor of the globally renowned Truenat platform. This partnership help democratize and increase access to timely and accurate diagnostic settings to affected patients, thus helping Molbio achieve its goal of providing complete testing solutions via the Truenat platform.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global point of care molecular diagnostics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Application s and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight and Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 1.1. Key Company Analysis
  • 3.1. Abbott Laboratories
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Becton, Dickinson and Co.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Bosch Healthcare Solutions GmbH
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Siemens Healthineers
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Thermo Fisher Scientific Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Point of Care Molecular Diagnostics Market by Application
    • 4.1.1. Influenza
    • 4.1.2. Mononucleosis
    • 4.1.3. Respiratory Infectious Disease
    • 4.1.4. Gastrointestinal Infectious Disease
    • 4.1.5. Sexually Transmitted Disease
    • 4.1.6. Others (prenatal testing, and endocrinology)
  • 4.2. Global Point of Care Molecular Diagnostics Market by End user
    • 4.2.1. Hospitals
    • 4.2.2. Homecare
    • 4.2.3. Others (decentralized labs)
  • 4.3. Global Point of Care Molecular Diagnostics Market by Technology
    • 4.3.1. PCR
    • 4.3.2. Genetic Sequencing
    • 4.3.3. Hybridization
    • 4.3.4. Microarray

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Accelerate Diagnostics
  • 6.2. Access Bio
  • 6.3. Ador Diagnostics
  • 6.4. ADT Biotech
  • 6.5. Akonni Biosystems
  • 6.6. Alveo Technologies
  • 6.7. Antelope Dx
  • 6.8. Applied BioCode
  • 6.9. Aureum Diagnostics
  • 6.10. Aus Diagnostics
  • 6.11. Baebies
  • 6.12. Beckman Coulter Diagnostics
  • 6.13. Binx Health
  • 6.14. Biocartis
  • 6.15. BioFire Diagnostics (bioMerieux)
  • 6.16. BioMerieux Diagnostics
  • 6.17. Bio-Rad Laboratories, Inc.
  • 6.18. Cepheid (Danaher)
  • 6.19. Credo Diagnostics Biomedical
  • 6.20. Cue Health